Related Experiment Video

Updated: Aug 28, 2025

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.2K

p21-activated kinase 1 (PAK1) as a therapeutic target for cardiotoxicity

Ping Guo1, Yufeng Liu1, Jingrong Feng1

  • 1The School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.

Archives of Toxicology
|September 18, 2022
PubMed

Insights

p21-activated kinase 1 (PAK1) plays a key role in heart cell death and inflammation. Understanding PAK1

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cellular Signaling

Background:

  • p21-activated kinase 1 (PAK1) is highly expressed in cardiac tissue.
  • PAK1 is an effector of Rac and cell division cycle protein 42 (Cdc42).
  • Research on PAK1's role in cardiotoxicity is ongoing and requires further investigation.

Purpose of the Study:

  • To review the role of PAK1 in cardiomyocyte programmed cell death (apoptosis, autophagy, pyroptosis).
  • To examine PAK1's involvement in oxidative stress and inflammatory responses in cardiotoxicity.
  • To explore PAK1-mediated contributions of the gut microbiome and microRNAs to cardiotoxicity.

Main Methods:

  • Literature review of existing studies on PAK1 and cardiotoxicity.
  • Analysis of signaling pathways implicated in PAK1-induced cardiotoxicity.
  • Examination of mitochondrial dysfunction and calcium homeostasis imbalance in PAK1-related cardiotoxicity.

Main Results:

  • PAK1 is implicated in multiple forms of programmed cardiomyocyte death.
  • PAK1 contributes to oxidative stress and inflammation via mitochondrial and calcium signaling.
  • Gut microbiome and microRNAs are identified as PAK1-mediated factors in cardiotoxicity.

Conclusions:

  • PAK1 is a significant mediator of cardiotoxicity through various cellular mechanisms.
  • PAK1 influences cardiotoxicity via interactions with the gut microbiome and microRNAs.
  • PAK1 presents a promising therapeutic target for cardiovascular diseases.
Keywords:
CardiotoxicityIntestinal microbiotaMicroRNAOxidative stressProgrammed cell deathp21-activated kinase 1

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.2K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
238
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K